8-K: Tevogen Bio Secures Up to $10 Million in Non-Dilutive Grant Funding to Advance Immunotherapy and AI Efforts

Tevogen Bio announces a grant agreement with KRHP LLC for up to $10 million to support the development of T cell therapeutics and expansion of its artificial intelligence initiatives.

Summary

• Tevogen Bio has entered into a grant agreement with KRHP LLC to receive up to $10 million in non-dilutive funding.
• The initial contribution is $2 million, with a potential additional $8 million contingent on KRHP LLC's review of Tevogen Bio's activities.
• The grant will support the development of T cell therapeutics for cancers and viral infections, as well as the expansion of Tevogen Bio's artificial intelligence efforts (Tevogen.AI).
• KRHP LLC is affiliated with an existing investor in Tevogen Bio.
• Tevogen Bio also has a previously announced $36 million loan agreement from 2Q24.

Sentiment

Score: 8

Explanation: The announcement of a significant non-dilutive grant is a positive development for Tevogen Bio, indicating financial support and confidence in its technology. The company's focus on AI and collaboration with Microsoft further contribute to a positive outlook.

Positives

• The grant funding is non-dilutive to existing shareholders.
• The funds will support the development of innovative T cell therapies.
• The grant will help expand Tevogen Bio's artificial intelligence capabilities.
• Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial.
• Tevogen Bio's key intellectual property assets are wholly owned by the company.

Negatives

• The additional $8 million of the grant is contingent on KRHP LLC's review of the company's activities, so it is not guaranteed.
• Tevogen Bio will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all.

Risks

• Tevogen Bio may need to raise additional capital to execute its business plan.
• The company faces risks related to clinical trials, regulatory approvals, and commercial development.
• There are risks associated with intellectual property protection.
• The company has a limited operating history.
• The additional $8 million of grant funding is contingent on KRHP LLC's review of the company's activities.

Future Outlook

Tevogen Bio plans to use the grant funding to further develop T cell therapies and expand its artificial intelligence efforts, aiming to address unmet needs in treating cancers and viral infections.

Management Comments

• Dr. Ryan Saadi, Chairman and CEO of Tevogen Bio, stated that AI-driven technologies could revolutionize drug discovery, accelerate development timelines, enhance patient accessibility, foster quicker innovation, and significantly reduce operating costs.

Industry Context

This announcement highlights the increasing interest and investment in immunotherapy and artificial intelligence within the biotech industry. Companies are actively seeking non-dilutive funding options to advance their research and development efforts. The collaboration with Microsoft on AI also reflects a growing trend of partnerships between biotech and technology companies.

Comparison to Industry Standards

• Securing non-dilutive funding is a common strategy for biotech companies, especially those in the clinical stage, to minimize shareholder dilution while advancing their pipelines.
• Comparable companies like Adaptimmune Therapeutics and Kite Pharma have also pursued grant funding and strategic partnerships to support their T cell therapy programs.
• The $10 million grant is a significant amount for a company of Tevogen Bio's size and stage, indicating confidence in their technology and potential.
• The collaboration with Microsoft on AI is similar to other biotech companies partnering with tech giants to leverage AI for drug discovery and development, such as Recursion Pharmaceuticals' partnership with NVIDIA.

Related Party Transactions

• KRHP LLC is affiliated with the spouse of Dr. Manmohan Patel, an existing investor in the Company and beneficial owner of more than 5% of the Company's common stock.

Stakeholder Impact

• Shareholders will benefit from the non-dilutive funding, which supports the company's growth without diluting their ownership.
• Employees will benefit from the increased resources for research and development.
• Patients may benefit from the development of new T cell therapies for cancers and viral infections.

Next Steps

• Tevogen Bio will deploy the grant funds to further expand efforts in AI and develop T cell therapeutics.
• KRHP LLC will review Tevogen Bio's activities to determine if the additional $8 million will be contributed.

Key Dates